Your search

Reset search

In authors or contributors

"Kotton, Camille N."

Results 17 resources

Abstracts

What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation

Stewart, A. G., & Kotton, C. N. - 2024 - Transplantation, 108(4), 884–897

Cytomegalovirus (CMV) is one of the most common infections occurring after solid organ transplantation. This high burden of disease, which incurs sizeable morbidity, may be worsening with the proportion of high-risk D+/R− solid organ transplantation recipients increasing in some regions globally. Cohort studies continue to support either universal prophylaxis or preemptive therapy as effective prevention strategies. Letermovir prophylaxis was noninferior to valganciclovir in adult high-risk...
The Next Outbreak Looms on the Horizon: Measles and Potential Impacts on Transplant Recipients

Al Jurdi, A., & Kotton, C. N. - 2024 - Transplantation, 108(10), 2012–2014
Oral Antibiotics for Treatment of Gram-Negative Bacteremia in Solid Organ Transplant Recipients: A Propensity Score Weighted Retrospective Observational Study

Nussbaum, E. Z., Koo, S., & Kotton, C. N. - 2024 - Clinical Infectious Diseases, ciae007

Background. We assessed the safety and efficacy of oral antibiotic step-down therapy for uncomplicated gram-negative blood stream infections in solid-organ transplant recipients. Methods. We identified all solid-organ transplant recipients within the Massachusetts General and Brigham and Women’s Hospital systems from 2016 to 2021 with uncomplicated gram-negative bacteremia involving an organism susceptible to an acceptably bioavailable oral antibiotic agent. Using inverse probability of...
Emerging Microbiology Diagnostics for Transplant Infections: On the Cusp of a Paradigm Shift

Azar, M. M., Gaston, D. C., Kotton, C. N., & Malinis, M. F. - 2020 - Transplantation, 104(7), 1358–1384

In light of the heightened risk for infection associated with solid organ and hematopoietic stem cell transplantation, rapid and accurate microbiology diagnostics are essential to the practice of transplant clinicians, including infectious diseases specialists. In the last decade, diagnostic microbiology has seen a shift toward culture-independent techniques including single-target and multiplexed molecular testing, mass-spectrometry, and magnetic resonance-based methods which have together...
Marijuana use in transplantation: A call for clarity

Levi, M. E., Montague, B. T., Thurstone, C., … Kotton, C. N. - 2019 - Clinical Transplantation, 33(2), e13456

Transplant centers have varying policies for marijuana (MJ) use in donors, transplant candidates, and recipients. Rationales for these differences range from concerns for fungal complications, impaired adherence, and drug interactions. This paper reviews the current status of MJ policies and practices in transplant centers and results of a survey sent to the American Society of Transplantation (AST) membership by the Executive Committee of the AST Infectious Diseases Community of...
Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors

Pierrotti, L. C., Carvalho, N. B., Amorin, J. P., … López-Vélez, R. - 2018 - Transplantation, 102(2S), S1–S7
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Anderson, T. C., Masters, N. B., Guo, A., … Dooling, K. L. - 2022 - MMWR. Morbidity and Mortality Weekly Report, 71(3), 80–84

What is already known about this topic? Immunocompromised persons experience a higher incidence of herpes zoster and related complications. On July 23, 2021, the Food and Drug Administration expanded the indication for use of recombinant zoster vaccine (RZV) to include immunodeficient or immunosuppressed adults. What is added by this report? On October 20, 2021, the Advisory Committee on Immunization Practices recommended 2 RZV doses for prevention of herpes zoster and related complications...
Utilization of increased risk for transmission of infectious disease donor organs in solid organ transplantation: Retrospective analysis of disease transmission and safety

Irwin, L., Kotton, C. N., Elias, N., … Fishman, J. A. - 2017 - Transplant Infectious Disease, 19(6), e12791

The inadequate supply of transplantable organs necessitates new approaches to organ availability. Serologies and nucleic acid testing (NAT) for hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV) are used in microbiologic screening of potential organ donors. Organs from donors considered at “high risk” (Centers for Disease Control and Prevention, CDC 1994) or “increased risk” (U.S. Public Health Service, PHS 2013) for transmission of viral infection to...
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation

Kotton, C. N., Kumar, D., Caliendo, A. M., … Group, on behalf of the T. T. S. I. C. C. - 2018 - Transplantation, 102(6), 900

Despite recent advances, cytomegalovirus (CMV) infections remain one of the most common complications affecting solid organ transplant recipients, conveying higher risks of complications, graft loss, morbidity, and mortality. Research in the field and development of prior consensus guidelines supported by The Transplantation Society has allowed a more standardized approach to CMV management. An international multidisciplinary panel of experts was convened to expand and revise evidence and...
What is the optimal antimicrobial prophylaxis to prevent postoperative infectious complications after liver transplantation? A systematic review of the literature and expert panel recommendations

Campos-Varela, I., Blumberg, E. A., Giorgio, P., … Group, the E. org W. - 2022 - Clinical Transplantation, 36(10), e14631

Background Antimicrobial prophylaxis is well-accepted in the liver transplant (LT) setting. Nevertheless, optimal regimens to prevent bacterial, viral, and fungal infections are not defined. Objectives To identify the optimal antimicrobial prophylaxis to prevent post-LT bacterial, fungal, and cytomegalovirus (CMV) infections, to improve short-term outcomes, and to provide international expert panel recommendations. Data sources Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane...
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients

Chou, S., Alain, S., Cervera, C., … Fournier, M. - 2023 - The Journal of Infectious Diseases, jiad293

BACKGROUND: This drug resistance analysis of a randomized trial includes 234 patients receiving maribavir and 116 receiving investigator-assigned standard therapy (IAT), where 56% and 24% respectively cleared cytomegalovirus DNA at week 8 (treatment responders). METHODS: Baseline and post-treatment plasma samples were tested for mutations conferring drug resistance in viral genes UL97, UL54 and UL27. RESULTS: At baseline, genotypic testing revealed resistance to ganciclovir, foscarnet or...
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

Kotton, C. N., Kumar, D., Manuel, O., … Group*, on behalf of T. T. S. I. C. C. - 2025 - Transplantation, 10.1097/TP.0000000000005374

Export
Training in transplant infectious diseases: A survey of infectious diseases and transplant infectious diseases fellows in the United States and Canada

Tan, S. K., Theodoropoulos, N., La Hoz, R. M., … On behalf of the American Society of Transplantation, I. D. C. of P. - 2018 - Transplant Infectious Disease, 20(4), e12915

Background Infectious diseases (ID) specialists with experience in managing infections in transplant recipients and other immunocompromised hosts are increasingly needed as these fields expand. Methods To evaluate experiences and identify trainee-described needs in transplant infectious diseases (TID) training, the American Society of Transplantation, Infectious Diseases Community of Practice (AST IDCOP) surveyed ID fellows across the United States and TID fellows in the United States and...
Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients

Linder, K. A., Kovacs, C., Mullane, K. M., … Kaul, D. R. - 2021 - Transplant Infectious Disease, 23(4), e13687

Background Few options are available for cytomegalovirus (CMV) treatment in transplant recipients resistant, refractory, or intolerant to approved agents. Letermovir (LET) is approved for prophylaxis in hematopoietic cell transplant (HCT) recipients, but little is known about efficacy in CMV infection. We conducted an observational study to determine the patterns of use and outcome of LET treatment of CMV infection in transplant recipients. Methods Patients who received LET for treatment of...
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum

Ljungman, P., Chemaly, R. F., Khawaya, F., … for the CMV Definitions Working Group of the Transplant Associated Virus Infections Forum - 2024 - Clinical Infectious Diseases, ciae321

Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians,...
Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America

Clemente, W. T., Pierrotti, L. C., Abdala, E., … Transplantation, on behalf of the working group on E. D. and T. M. in S.-O. - 2018 - Transplantation, 102(2), 193–208

The Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America clinical practice guideline is intended to guide clinicians caring for solid-organ transplant (SOT) donors, candidates and recipients regarding infectious diseases (ID) issues related to this geographical region, mostly located in the tropics. These recommendations are based on both systematic reviews of relevant literature and expert opinion from both...
Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America

Clemente, W. T., Pierrotti, L. C., Abdala, E., … Transplantation, on behalf of the working group on E. D. and T. M. in S.-O. - 2018 - Transplantation, 102(2), 193

The Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America clinical practice guideline is intended to guide clinicians caring for solid-organ transplant (SOT) donors, candidates and recipients regarding infectious diseases (ID) issues related to this geographical region, mostly located in the tropics. These recommendations are based on both systematic reviews of relevant literature and expert opinion from both...